Key stats
About Amplify ETF Trust Amplify Weight Loss Drug & Treatment ETF
Home page
Inception date
May 21, 2024
Structure
Open-Ended Fund
Replication method
Physical
Dividend treatment
Distributes
Distribution tax treatment
Qualified dividends
Income tax type
Capital Gains
Max ST capital gains rate
39.60%
Max LT capital gains rate
20.00%
Primary advisor
Amplify Investments LLC
Distributor
Foreside Fund Services LLC
THNR focuses on the weight loss industry. The fund tracks an index that invests in companies involved in manufacturing and enabling GLP-1 agonist pharmaceutical businesses. GLP-1 agonists seek to lower blood sugar levels, reduce appetite, and promote fullness, with the ultimate potential for weight loss. Starting with an initial universe of companies from the developed markets, the index selects: 1) drug manufacturers, which are firms with GLP-1 agonist drugs that either have been launched or are currently in Food and Drug Administration (FDA) clinical trials, and 2) enablers, which are companies engaged in the outsourced development and manufacturing, as well as the production and distribution of GLP-1 agonist drugs. Drug manufacturers comprise 70% of the portfolio, while enablers cover the remaining 30%. Holdings within each segment are market cap-weighted, subject to individual security capping. The index reconstitutes and rebalances quarterly.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Stocks99.38%
Health Technology94.39%
Health Services4.98%
Bonds, Cash & Other0.62%
Mutual fund0.38%
Cash0.24%
Stock breakdown by region
North America56.69%
Asia22.98%
Europe20.33%
Latin America0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings
Dividends
Dividend payout history
Assets under management (AUM)
Fund Flows
Frequently Asked Questions
THNR invests in stocks. The fund's major sectors are Health Technology, with 94.39% stocks, and Health Services, with 4.98% of the basket. The assets are mostly located in the North America region.
THNR top holdings are Eli Lilly and Company and Novo Nordisk A/S Sponsored ADR Class B, occupying 12.17% and 7.74% of the portfolio correspondingly.
THNR last dividends amounted to 0.14 USD. The year before, the issuer paid 0.08 USD in dividends, which shows a 42.16% increase.
THNR assets under management is 2.99 M USD. It's fallen 1.95% over the last month.
THNR fund flows account for 567.15 K USD (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.
Yes, THNR pays dividends to its holders with the dividend yield of 0.36%. The last dividend (Dec 31, 2024) amounted to 0.22 USD. The dividends are paid annually.
THNR shares are issued by Amplify Holding Co. LLC under the brand Amplify. The ETF was launched on May 21, 2024, and its management style is Passive.
THNR expense ratio is 0.59% meaning you'd have to pay 0.59% of your investment to help manage the fund.
THNR follows the VettaFi Weight Loss Drug & Treatment Index - Benchmark TR Net. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
THNR invests in stocks.
THNR price has fallen by −0.21% over the last month, and its yearly performance shows a −14.84% decrease. See more dynamics on THNR price chart.
NAV returns, another gauge of an ETF dynamics, have fallen by −0.72% over the last month, showed a 2.04% increase in three-month performance and has increased by 0.21% in a year.
NAV returns, another gauge of an ETF dynamics, have fallen by −0.72% over the last month, showed a 2.04% increase in three-month performance and has increased by 0.21% in a year.
THNR trades at a premium (0.29%) meaning the ETF is trading at a higher price than the calculated NAV.